Cargando…

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

BACKGROUND: To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to characterise the pharmacokinetics (PK)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185947/ https://www.ncbi.nlm.nih.gov/pubmed/21878940 http://dx.doi.org/10.1038/bjc.2011.332

Ejemplares similares

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
por: Padda, Sukhmani K., et al.
Publicado: (2011)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer
por: Schellens, J H M, et al.
Publicado: (2003)

Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013)

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
por: Patnaik, A, et al.
Publicado: (2014)

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
por: Kast, R. E.
Publicado: (2015)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib
por: Yang, Jin-zhao, et al.
Publicado: (2021)

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
por: Goss, Glenwood D., et al.
Publicado: (2016)

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
por: Garon, E.B., et al.
Publicado: (2023)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib hydrochloride: an anticancer agent
por: Selvanayagam, S., et al.
Publicado: (2008)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
por: Schöttle, Jakob, et al.
Publicado: (2015)

Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
por: Samadder, N Jewel, et al.
Publicado: (2023)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Erlotinib-induced dry eye
por: Ravisankar, Rashmita, et al.
Publicado: (2023)

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer
por: Krzakowski, M., et al.
Publicado: (2013)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash
por: Lee, Won Kil, et al.
Publicado: (2023)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
por: Fatani, Wafa K., et al.
Publicado: (2023)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival
por: Kainis, Ilias, et al.
Publicado: (2018)

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
por: Yoh, Kiyotaka, et al.
Publicado: (2016)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Cutaneous Leukocytoclastic Vasculitis Associated with Erlotinib
por: Sawada, Takahiro, et al.
Publicado: (2016)

Toxicité cutanée à l'erlotinib
por: Bourra, Hayat, et al.
Publicado: (2013)

Stability and Formulation of Erlotinib in Skin Creams
por: Nguyen, David, et al.
Publicado: (2022)

Metformin and erlotinib synergize to inhibit basal breast cancer
por: Lau, Ying-Ka Ingar, et al.
Publicado: (2014)

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
por: Fernando, Romaine I., et al.
Publicado: (2016)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d9culk3htfqgncdss08g4837pt